CARDIAC TISSUE MODELS AND METHODS OF USE THEREOF

Tech ID: 27113 / UC Case 2017-043-0

Patent Status

Patent Pending

Brief Description


Tissue engineering approaches have the potential to increase the physiologic relevance of human iPS-derived cells, such as cardiomyocytes (iPS-CM). However, forming Engineered Heart Muscle (EHM) typically requires >1 million cells per tissue. Existing miniaturization strategies involve complex approaches not amenable to mass production, limiting the ability to use EHM for iPS-based disease modeling and drug screening. Micro-scale cardiospheres are easily produced, but do not facilitate assembly of elongated muscle or direct force measurements.

 

UC Berkeley researchers have developed a 3D filamentous fiber matrix that combines features of EHM and cardiospheres: Micro-Heart Muscle (μHM) arrays, in which elongated muscle fibers are formed in an easily fabricated template, with as few as 2,000 iPS-CM per individual tissue. Within μHM, iPS-CM exhibit uniaxial contractility and alignment, robust sarcomere assembly, and reduced variability and hypersensitivity in drug responsiveness, compared to monolayers with the same cellular composition. μHM mounted onto standard force measurement apparatus exhibited a robust Frank-Starling response to external stretch, and a dose-dependent inotropic response to the β-adrenergic agonist isoproterenol.

 

Suggested uses


  • Research tool to study cardiomyocyte maturation, disease and cardiotoxicology in vitro
  • Drug discovery

 

Advantages

  • Easily fabricated and can be mass produced
  • A small number of cells required to form μHM

Publication

Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses 

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

cardiac, disease modeling, contraction force measurement, cardiomyopathy, stem cells

Categorized As